Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.54 |
| ▸ | CTSC | P53634 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.51 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14416298 | 0.91 | CYP1A2 (0.51) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1329815 | 0.88 | MME (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL6047673 | 0.88 | MME (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1329817 | 0.88 | MME (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL8692954 | 0.87 | MME (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8789703 | 0.87 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8788898 | 0.87 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL14963151 | 0.87 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL8692950 | 0.87 | MME (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5594394 | 0.86 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3650464-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2020-05-13 | — | — | EP | disclosed |
| EP-3647319-A1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019007383-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | 凯惠科技发展(上海)有限公司 | 2019-01-10 | — | — | WO | disclosed |
| WO-2019001459-A1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | 凯惠科技发展(上海)有限公司 | 2019-01-03 | — | — | WO | disclosed |
| US-9073868-B2 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-8785386-B2 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8669229-B2 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20140024640-A1 | Benzazepine Derivatives Useful as Vasopressin Antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024619-A1 | Benzazepine Derivatives Useful as Vasopressin Antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| EP-2374798-B1 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2374798-A1 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110071084-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071084-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | AVPR2, AVPR1B, AVPR1A | ALPI 4717/4885PKM 2225/4885PTGS1 861/4885 |
| US-20140024619-A1 | Benzazepine Derivatives Useful as Vasopressin Antagonists | AVPR2, AVPR1B, AVPR1A | ALPI 4718/4885PKM 2097/4885PTGS1 819/4885 |
| US-20140024640-A1 | Benzazepine Derivatives Useful as Vasopressin Antagonists | AVPR2, AVPR1B, AVPR1A | ALPI 4718/4885PKM 2097/4885PTGS1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.